1. Home
  2. ALT vs AXIN Comparison

ALT vs AXIN Comparison

Compare ALT & AXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • AXIN
  • Stock Information
  • Founded
  • ALT 1997
  • AXIN 2025
  • Country
  • ALT United States
  • AXIN United Kingdom
  • Employees
  • ALT N/A
  • AXIN N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • AXIN
  • Sector
  • ALT Health Care
  • AXIN
  • Exchange
  • ALT Nasdaq
  • AXIN Nasdaq
  • Market Cap
  • ALT 333.6M
  • AXIN 272.1M
  • IPO Year
  • ALT N/A
  • AXIN 2025
  • Fundamental
  • Price
  • ALT $3.93
  • AXIN $9.97
  • Analyst Decision
  • ALT Strong Buy
  • AXIN
  • Analyst Count
  • ALT 6
  • AXIN 0
  • Target Price
  • ALT $17.40
  • AXIN N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • AXIN 28.8K
  • Earning Date
  • ALT 11-11-2025
  • AXIN 01-01-0001
  • Dividend Yield
  • ALT N/A
  • AXIN N/A
  • EPS Growth
  • ALT N/A
  • AXIN N/A
  • EPS
  • ALT N/A
  • AXIN N/A
  • Revenue
  • ALT $20,000.00
  • AXIN N/A
  • Revenue This Year
  • ALT N/A
  • AXIN N/A
  • Revenue Next Year
  • ALT N/A
  • AXIN N/A
  • P/E Ratio
  • ALT N/A
  • AXIN N/A
  • Revenue Growth
  • ALT N/A
  • AXIN N/A
  • 52 Week Low
  • ALT $2.90
  • AXIN $9.93
  • 52 Week High
  • ALT $11.16
  • AXIN $9.98
  • Technical
  • Relative Strength Index (RSI)
  • ALT 52.80
  • AXIN N/A
  • Support Level
  • ALT $3.85
  • AXIN N/A
  • Resistance Level
  • ALT $4.06
  • AXIN N/A
  • Average True Range (ATR)
  • ALT 0.20
  • AXIN 0.00
  • MACD
  • ALT 0.02
  • AXIN 0.00
  • Stochastic Oscillator
  • ALT 57.35
  • AXIN 0.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About AXIN Axiom Intelligence Acquisition Corp 1 Class A Ordinary Shares

Axiom Intelligence Acquisition Corp 1 is a blank check company.

Share on Social Networks: